Adverse drug reactions to 5-fluorouracil (5-FU)-based chemotherapy have been reported to be due, in part, to genetic variants of the genes for the drug-related enzymes thymidylate synthase (TS; TYMS gene), methylenetetrahydrofolate reductase (MTHFR gene) and dihydropyrimidine dehydrogenase (DPD; DPYD gene). This study investigated whether selected genetic variants of the TYMS, MTHFR and DPYD genes predict 5-FU-related early toxicity. The prevalence of the genetic variants was determined in 122 colorectal cancer patients and in a reference population of 320 blood donors. Subgroup analysis of 68 of the colorectal cancer patients was carried out to determine the relationship between selected gene variants detected in peripheral mono nuclear cells and tolerability during the first or second cycle of 5-FU based treatment. Toxicity was linked to the TYMS 2R/2R variant (relative risk [RR] 1.66; sensitivity 0.37; specificity 0.77) and to the MTHFR c1298 C/C genetic variant (RR 1.77; sensitivity 0.17; specificity 0.91). Patients with the genetic variant IVS14+1 G/A or c1896 C/T in the DPYD gene had a statistically significant increased risk of experiencing toxicity (RR 2 and 6, respectively), both having a high specificity (0.97 and 0.98, respectively) and low sensitivity (0. 04 and 0.13, respectively) . It is concluded that pre-treatment detection of genetic variants can help to predict early toxicity experienced by patients receiving 5-FU-based chemotherapy.
Introduction
For more than five decades, 5-fluorouracil (5-FU) has been an important component of many standard treatments in the multimodal therapy of colorectal cancer (CRC). 1 -4 This applies to the treatment of advanced disease and as adjuvant therapy. Unfortunately, 5-FU induces grade III -IV MH Kristensen, PL Pedersen, GV Melsen et al. Gene variants in DPYD, MTHFR and TYMS predict 5-FU-related toxicity toxic side-effects in 20 -30% and toxicityrelated death in 0.5% of patients. 1 Many of these adverse events occur in an adjuvant setting, in patients that have been potentially cured of their disease following surgery. 5 -8 Capecitabine, an oral pro-drug of 5-FU, has been developed to provide a more selective and less toxic alternative to 5-FU. 9 Identification of patients at risk of druginduced side-effects before 5-FU treatment could enable timely reduction or selection of alternative treatment. 10 Little is known about predictors of toxicity in patients with CRC treated with 5-FU-based chemotherapy. It is widely recognized that confounding environmental, physiological and inherited genetic factors play an important role in the variability of treatment outcome. Pharmacogenetic screening may have the potential to identify patients who are likely to experience severe toxicity. As toxicity remains the major limitation to adequate dosing, the ability to predict toxicity before administration of chemotherapy would probably result in improved patient outcomes.
Thymidylate synthase (TS; encoded by the TYMS gene) is a key enzyme in nucleotide biosynthesis and is the main intracellular target of 5-FU. 11,12 TS forms a ternary complex with 5,10-methylenetetrahydrofolate (5,10-CH 2 FH 4 ) and the active metabolite of 5-FU (5-fluoro-2′-deoxyuridine-5′-monophosphate [FdUMP] ) resulting in TS inhibition and cell death ( Fig. 1 ). Three genetic variants affecting the expression of TYMS are hypothesized to be associated with an increased risk of toxicity after 5-FU FIGURE 1: Genetic variants in the drug-related enzymes dihydropyrimidine dehydrogenase (DPD), thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) are thought to be able to predict 5-fluorouracil (5-FU)-induced toxicity (capecitabine is a 5-FU pro-drug; 5-CH 3 FH 4 , 5-methyltetrahydrofolate; 5,10-CH 2 FH 4 , 5,10-methylenetetrahydrofolate; dTMP, deoxythymidine monophosphate; dUMP, deoxyuracil monophosphate; FdUrd, 5-fluoro-2′-deoxyuridine; FdUMP, 5fluoro-2′-deoxyuridine-5′-monophosphate dTMP DNA synthesis Gene variants in DPYD, MTHFR and TYMS predict 5-FU-related toxicity administration: 13 -16 (i) a 28-bp tandem repeat variant in the TYMS enhancer region (TYMSER 2R/2R, 2R/3R and 3R/3R); 17 (ii) a single nucleotide polymorphism (SNP) at the 12th nucleotide of the second repeat in the 3R allele leading to a tri-allelic locus (2R, 3RC and 3RG); 18 and (iii) a 6-bp deletion at bp 1494 in the 3′-untranslated region (UTR). 19, 20 It has been proposed that high levels of TYMS expression protect cells from the cytotoxic effect of 5-FU and, as a result, lead to decreased toxicity. 15 Optimal inhibition of TS requires elevated cellular concentrations of 5,10-CH 2 FH 4 , which is degraded by the enzyme, methylenetetrahydrofolate reductase (MTHFR) encoded by the MTHFR gene. 21, 22 The MTHFR 677 C>T and 1298 A>C polymorphisms are common gene variants associated with low MTHFR activity. 23 -27 Patients with the variant MTHFR allele will have elevated cellular 5,10-CH 2 FH 4 and, as a consequence, increased sensitivity to 5-FUbased treatment and, possibly, an elevated risk of toxicity. 24,25,28 -30 Dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene, deactivates > 80% of administered standard doses of 5-FU. 31 -33 Impairment of this pyrimidine degradation pathway leads to toxic accumulation of the drug in 5-FU treated patients. This may also affect patients treated with capecitabine. 34 There are > 40 gene variants that have been identified in the DPYD gene, some of which are associated with a lack of activity. 33 The most frequently described genetic variant, in patients with partial or complete DPD deficiency, is a G>A mutation within the 5′splicing site of intron 14 (IVS14+1 G>A). 35 This truncating mutation appears to explain only a limited number of the serious side-effects attributed to DPD deficiency. 36 Moreover, only a few mis-sense mutations are known to interfere directly with protein structure, cofactor binding and electron transfer of the DPD enzyme (e.g. c85 T>C, c496 A>G, c703 C>T, c1601 G>A, c1679 T>G, c1896 T>C, c2846 A>T). 37, 38 Until now, the impact of common nonsynonymous gene variants on fluoropyrimidine-induced toxicity remains unclear and systematic association studies are needed. The purpose of the present study was to determine the prevalence of selected genetic variants and their association with 5-FU-related early toxicity.
Patients and methods

PATIENTS AND TREATMENT
Blood samples from CRC patients who had been treated in the Department of Oncology, Hospital South, Naestved, Denmark, between January 2005 and March 2006, and from normal blood donors were used to determine the prevalence of the selected genetic variants. This retrospective study also included a subgroup analysis of patients who had received chemotherapy for advanced carcinomas as adjuvant or as palliative therapy.
The local ethical committee at Hospital South, Naestved, Denmark, approved the study protocol and written informed consent was obtained from all participants. 
TREATMENT REGIMENS
TOXICITY
Side-effects that are typically associated with 5-FU treatment, such as neutropenia, thrombopenia, diarrhoea, nausea and vomiting, neurotoxicity, cardiac toxicity, alopecia and hand-foot syndrome, 1,40 were documented within the first two cycles of therapy. The toxicity assessment was based on the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTC AE) version 3.0 (https://webapps. ctep.nci.nih.gov/webobjs/ctc/webhelp/ Welcome_to_CTCAE_1.htm). Grading of toxicity was done without knowledge of the genotyping results. Paraesthesia and dysaesthesia were excluded from the analysis in patients treated with the FOLFOX regimen, as these symptoms can be attributed to oxaliplatin. 41 -43 
MOLECULAR BIOLOGY METHODS
Blood samples were analysed for the presence of selected genetic variants. DNA was extracted from whole blood cells using a modified version of the alkaline extraction method. 44 Polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses were carried out using the primers and restriction enzymes listed in Table 1 . The PCR reaction mix consisted of 25 µl of reaction mixture containing 1.25 mM magnesium chloride (Fermentas, Copenhagen, Denmark), 2 mM deoxynucleotide triphosphates (Fermentas), 2.5 µl of dimethyl sulphoxide (Sigma-Aldrich, Steinheim, Germany) and 40 pmol of each primer. The thermal cycling programme involved preliminary denaturation at 94°C for 5 min, followed by 36 cycles of denaturation at 94°C, annealing at 56°C for 60 s, and elongation at 72°C for 60 s, followed by a final elongation step at 72°C for 7 min. Then, 15 µl of the PCR reaction were digested at 37°C for 1 h in a 20 µl reaction volume with the restriction enzymes listed in Table 1 and the digestion products were resolved using 2% agarose gels and visualization under UV.
STATISTICAL ANALYSIS
Statistical analyses were carried out using the SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Statistical differences were assessed by Pearson's χ 2 -test. The correlation between the presence of a genetic variant and toxicity was evaluated by sensitivity and specificity and relative risk (RR). A Mantel-Haenszel test, controlling for confounding variables, was used to test whether two dichotomous variables (toxicity and genotype) were affected by the drug regimen. A P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS AND CLINICAL DATA
Blood samples from 122 CRC patients and 320 normal blood donors were used to determine the prevalence of the selected genetic variants. Subgroup analysis of 68 of the 122 CRC patients (30 females, 38 males) who had been treated for advanced carcinomas with chemotherapy as adjuvant or as palliative therapy was also included. The mean ± SD age of these 68 patients was 67 ± 11.5 years (range 42 -89 years). The site of the primary tumour was colonic in 58 and rectal in 10 cases. The primary stage, according to tumour, node, metastasis (TNM) classification of the American Joint Committee on Cancer, 45 was stage II in three patients, stage III in 56 and stage IV in nine. The numbers of patients treated with the 5-FU-based regimens were: Nordic, n = 24; capecitabine, n = 17; and MH Kristensen, PL Pedersen, GV Melsen et al. The antisense primers were modified holding a HinfI control cleavage site. 28 For additional information contact the corresponding author.
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TYMS, thymidylate synthase gene; TYMSER, thymidylate synthase enhancer region; SNP, single nucleotide polymorphism; MTHFR, 5,10-methylenetetrahydrofolate reductase gene; DPYD, dihydropyrimidine dehydrogenase gene. 
PREVALENCE OF TYMS, MTHFR AND DPYD GENE VARIANTS
There was no statistically significant difference in the frequencies of the genetic variants between the reference population (normal blood donors) and CRC patients (data not shown). The frequency of the TYMSER genotype variant 2R/2R was 28%, 2R/3R was 50% and 3R/3R was 22%. The frequency of the TYMS SNP was 55% for G/G, 35% for G/C and 10% for C/C. The two gene variants led to a tri-allelic locus (2R, 3RG and 3RC) and their distribution in the different genotypes was 2R/2R (28%), 2R/3RC (24%), 2R/3RG (30%), 3RC/3RG (6%), 3RC/3RC (9%) and 3RG/3RG (3%). The distribution of the TYMS 3′-UTR gene variants was 12% for del 6 bp/del 6 bp, 38% for ins 6 bp/del 6 bp and 50% for ins 6 bp/ins 6 bp. The frequency of the different MTHFR genotype variants was 46% for 677 C/C (wild-type), 44% for C/T and 10% for T/T. The distribution of the MTHFR gene variants located at bp 1298 was 44% for A/A (wild type), 44% for A/C and 12% for C/C.
The allelic frequency of the heterozygote DPYD IVS14+1 G>A, the c703 C>T, the c1601 G>A and the c2846 T>A was 2%, 1%, 3% and 3%, respectively. No homozygous carriers for these DPYD SNPs were detected. The c85 T>C, c496 G>A and c1896 T>C heterozygous and homozygous frequencies were 37%, 19% and 17%, and 5%, 2% and 1%, respectively. These distributions are in close agreement with the frequencies previously described in Caucasian populations. 15,25,33,35,46 -54 All three genotype variants were in Hardy-Weinberg equilibrium.
ANALYSIS OF TOXICITY
Overall, early toxicity (first or second cycle of treatment) appeared in 35% (24/68) of patients, with 13% (9/68) showing toxicity of grades III -IV (Table 2) . Toxicity of grades III -IV was the predominant level in the Nordic regimen (83%), whereas grades I -II toxicity predominated in the FOLFOX (67%) and capecitabine (100%) regimens. Of the 24 patients who showed early toxicity, the predominant toxic side-effect of the FOLFOX and Nordic regimens was bone marrow depression (BMD) (44% [8/18 patients]) whereas, for capecitabine, diarrhoea was the predominant side-effect (67% [4/6 patients]). Skin toxicity was observed in one patient in each treatment regimen (we included oesophagitis [patient 10] and mucositis [patient 17] within the definition of skin toxicity). Two patients experienced cardiac toxicity during the FOLFOX regimen. Peripheral neuropathy occurred in 8.8% (6/68) of patients (all receiving FOLFOX); these patients were excluded from further analysis because this adverse effect is known to be attributed to oxaliplatin. None of the patients had their treatment stopped due to toxicity. Three patients with grades III -IV toxicity continued their treatment with a 10 -50% reduction in dose.
All patients with 5-FU-associated toxicity recovered and no toxicity-related deaths were observed. No distinct therapy appeared to be particularly linked to a higher incidence of toxicity; incidence rates were 38% (9/24 patients), 35% (6/17 patients) and 33% (9/27 patients) for the Nordic, capecitabine and FOLFOX regimens, respectively. To address a possible effect of the different types of 5-FUbased regimens on the toxicity risk associated with the different genotypes, a Mantel-Haenszel test was performed, which demonstrated that the occurrence of toxicity was independent of the regimen used. 
MH Kristensen, PL Pedersen, GV Melsen et al. Gene variants in DPYD, MTHFR and TYMS predict 5-FU-related toxicity
CORRELATION BETWEEN THE GENETIC VARIANTS AND TOXICITY
Analysis of the association between the presence of a genetic variant and toxicity was performed and the sensitivity, specificity and RR of toxicity for each genetic variant and for relevant combinations was characterized (Table 3) . A RR of 1.65 (specificity, 0.77; sensitivity, 0.37; P = 0.01) of experiencing toxicity was found for the TYMS 2R/2R homozygous individuals (n = 9). An association between the TYMS 6-bp deletion and toxicity was not observed (data not shown). There was no significant effect of the G>C SNP at the 12th nucleotide of the second repeat of the 3R allele in the occurrence of toxicity (data not shown). Combining the TYMSER and SNP into high (2R/3RG, 3RG/3RC, 3RG/3RG) and low (2R/2R, 2R/3RC, 3RC/3RC) TYMS expression did not result in a significant difference in occurrence of toxicity between the two groups (data not shown).
No effect of the presence of the homozygous MTHFR genetic variant (T/T) located at bp 677 was seen (data not shown), but a 1.38-fold increase in the RR of experiencing toxicity was found in MTHFR heterozygous subjects (C/T) (n = 14; specificity and sensitivity of 0.58; P = 0.03). Subjects with the homozygous MTHFR 1298 C/C genotype showed an increased RR of 1.77 (n = 4; specificity of 0.91; sensitivity of 0.17; P = 0.008) of experiencing toxicity. Two subjects were found to be heterozygous for the DPYD IVS14+1 G/A variant; one experienced toxicity (grade II BMD) (specificity 0.97; sensitivity 0.04; RR 2; P = 0.03). The DPYD c1896 C/T gene variant was detected in four patients, two of them individually (one experiencing toxicity [grade IV BMD]; specificity 0.98; sensitivity 0.13; RR 6; P = 0.01) and two of them combined with DPYD c85 T>C (both experiencing toxicity [grade I BMD and grade III diarrhoea]; specificity 1; sensitivity 0.08).
An additional six compound TYMSER, thymidylate synthase gene; MTHFR, 5,10-methylenetetrahydrofolate reductase gene; DPYD, dihydropyrimidine dehydrogenase gene. a Two of the three patients harbouring the c1896 mutation and experiencing toxicity were compound heterozygous, both additionally having the c85 T/C mutation. Gene variants in DPYD, MTHFR and TYMS predict 5-FU-related toxicity heterozygous patients were also found. One patient experiencing toxicity harboured the DPYD c85 T>C in combination with c496 A>G (grade III BMD; specificity 0.93; sensitivity 0.04). Five compound DPYD heterozygous patients did not experience toxicity (three c85 T>C + c496 A>G, one c85 T>C + c2846 A>T, and one c496 A>G + c703 C>T). The c703 C>T and c2846 A>T DPYD gene variants had no influence, when present in combination, in terms of causing toxicity. The c1679 T>G DPYD genetic variant was not detected in this study.
Discussion
A mortality rate of 0.5% and grades III -IV toxic side-effects of 20 -30% have been reported in patients treated with 5-FU bolus or continuous infusion for advanced cancer or as adjuvant therapy. 39,55 -58 Analysis of the genetic variation of the genes for drugrelated enzymes is thought to be a useful approach for the prediction of adverse effects and treatment outcome. Considering the frequent use of 5-FU, it would be important to identify patients prone to 5-FU-related toxicity prior to treatment. To date, no detection strategy or handling procedure has been proposed. The present study focused on the genetic variants of TYMS, MTHFR and DPYD to determine a possible association with an early adverse response to 5-FU in patients with colorectal cancer.
Neither the frequency nor the type of adverse events experienced by the patients in this study were extraordinary. The predominant adverse effect in the FOLFOX and Nordic regimens was BMD, whereas diarrhoea predominated in the capecitabine regimen. A total of 13% of patients experienced grade III -IV toxicities; all in accordance with previously published results. 10 Oxaliplatin, in combination with 5-FU, is known to result in higher frequencies of peripheral neuropathy than 5-FU alone. 39 In the present study, 22% (6/27 patients) of the patients receiving the FOLFOX regimen experienced peripheral neuropathy compared with none of the patients on the Nordic or capecitabine regimens. The overall incidence of 5-FU-related cardiac toxicity was 2.9% (2/68 patients), which is in accordance with previously published results. 59 Being able to predict drug toxicity would be of importance in improving the efficacy of cancer therapy. Patients homozygous for the 2R variant of the TYMS gene experienced a significantly higher incidence of toxicity. These results are similar to those of Lecomte et al. 15 In their study, however, patients with the TYMS 2R/2R genotype were 20-times more likely to experience severe toxicity compared with 3R/3R carriers. 15 In contrast, only a modest (1.65) increased RR was observed in the present study.
Mandola et al. 60 suggested that the impact of a 3R genotype on TS transcriptional activation may ultimately be related to the presence of the G>C SNP in the second repeat of the 3R allele. The TYMS 3′-UTR polymorphism found in the homozygous form in 12% of the population was tested individually and in combination with TYMSER for association with toxicity. No significant correlation between either the presence of the TYMS 3′-UTR SNP or between the TYMS 6-bp deletion and toxicity was found in the present study.
Given the interplay between TS and MTHFR in mediating 5-FU cytotoxicity, it was investigated whether common MTHFR SNPs predict toxicity. It was found that the common MTHFR 1298 C/C genetic variant was predictive of toxicity with a RR of 1.77. These results are in accordance with previously published results indicating an effect on toxicity of decreased MTHFR activity. 29, 61 A curious finding, also noted by Gene variants in DPYD, MTHFR and TYMS predict 5-FU-related toxicity Sharma et al., 62 was that the MTHFR 677 C/T heterozygous genotype significantly predicted toxicity (RR 1.38; P = 0.03).
It has been suggested that TYMS and MTHFR genetic variants are associated with colorectal carcinogenesis. In the present study, similar allele frequencies were observed in CRC patients and controls. These data support the proposal by Chen et al. 63 that suggests that the TYMS or the MTHFR genotypes alone are not associated with colorectal/adenoma risk. In conclusion, altered TYMS and MTHFR genotypes seem to be a significant predictive factor for some of the 5-FU-related toxicity, supporting the theory that 5-FU, independent of regimen, exerts its cytotoxic effects, at least partly, by inhibiting TS.
Deficiency of DPD caused by the presence of genetic variants has been reported to be responsible for about 50% of severe 5-FUrelated toxicity. 33, 38, 64 The exact determination of relevant DPYD variants, their respective frequencies, and their effects on DPD activity, the patient's tolerance to 5-FU and subsequent patient handling, remain to be determined. 57 We believe that testing only for the DPYD splice-site mutation, IVS14+1 G>A, as has been recommended by some authors, is insufficient and would generate many false negative results. 35, 37 The positive predictive value of IVS14+1 G>A was limited in the present study as the risk for carriers to develop toxicity was only approximately 50%, confirming recent findings by other investigators. 65 Of the seven additional DPYD SNPs screened for in the present study population, only c1896 T>C was found to be highly correlated with early 5-FU-related toxicity. This mutation, which is much less frequently reported in the literature than IVS14+1 G>A, had a high prevalence in this population of Danish Caucasian patients (5.5%). The compound heterozygous genotype of patients 7 and 20 (c85 T/C and c1896 C/T), both experiencing toxicity, has to our knowledge not previously been described.
The frequent (39% heterozygous) c85 C/T variant had little or no effect on 5-FU toxicity. Although previous studies have reached contradictory conclusions about its possible role in 5-FU toxicity, the results agree with those of Collie-Duguid et al. 36 and Morel et al. 65 in that it could be characterized as a common and pharmacokinetically inconsequential polymorphism. 66 Similarly, although the c703 C>T and c1601 G>A variants have previously been suspected of lowering DPYD gene expression, the present study suggested that these mutations have little to no clinical effect; the c1679 T>G DPYD genetic variant was not detected.
Detection of the DPYD gene SNP cannot predict all severe toxic side-effects that occur in the first or second cycle of therapy. The present study suggested, however, that DPYD SNP detection could potentially be used to avoid about 20% of all early 5-FU-related toxicities. The results raise the question of the cause of 5-FU toxicity in the remaining approximate 80% of patients. Possible explanations include: (i) additional DPYD mutations that can affect pharmacokinetics may yet be discovered and remain to be analysed; or (ii) mutations or SNPs in other enzymes involved in 5-FU catabolism. For example, dihydropyrimidase has been reported as such an enzyme. 58 Furthermore, modulation by folinic acid, body mass index, administration regimen and sex have been shown to be independent risk factors for 5-FU-related toxicity. 40, 67, 68 The small size of the present study excluded the analysis of a correlation between these factors and toxicity. The analyses of the different diplotypes were not integrated and their possible synergistic effects on 5-FU-based toxicity cannot be excluded.
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The fact that all toxicity grades were included could be the cause of some of the discrepancies with previously published results.
A number of factors can contribute to inconsistent findings in association studies. These include the type and dose of the TS inhibitors administered, cancer type, the stage and grade of the tumour, patient ethnicity, limited sample size, misclassification of phenotype, and population structure. 69, 70 The results of the present study imply that prior to 5-FU administration a blood sample from the patient should be checked for the presence of the IVS14+1 G/A or c1896 C/T gene variants. Identification of patients with an increased risk of developing severe 5-FUassociated toxicity would allow either doseadaption, or the application of new nonfluoropyrimidine-based chemotherapeutic drugs or a different 5-FU schedule, in order to improve quality of life and reduce healthcare costs. 71, 72 The role of the TYMS, MTHFR and DPYD gene variants in predicting toxicity in patients treated with 5-FU-based chemotherapy should continue to be investigated. Thus, large-scale population screening studies have been initiated.
